Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China.
Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China.
Front Endocrinol (Lausanne). 2023 Jul 27;14:1220426. doi: 10.3389/fendo.2023.1220426. eCollection 2023.
Metabolic syndrome is a complex metabolic disorder that often clinically manifests as obesity, insulin resistance/diabetes, hyperlipidemia, and hypertension. With the development of social and economic systems, the incidence of metabolic syndrome is increasing, bringing a heavy medical burden. However, there is still a lack of effective prevention and treatment strategies. Fibroblast growth factor 21 (FGF21) is a member of the human FGF superfamily and is a key protein involved in the maintenance of metabolic homeostasis, including reducing fat mass and lowering hyperglycemia, insulin resistance and dyslipidemia. Here, we review the current regulatory mechanisms of FGF21, summarize its role in obesity, diabetes, hyperlipidemia, and hypertension, and discuss the possibility of FGF21 as a potential target for the treatment of metabolic syndrome.
代谢综合征是一种复杂的代谢紊乱，常以肥胖、胰岛素抵抗/糖尿病、血脂异常和高血压为临床特征。随着社会经济系统的发展，代谢综合征的发病率不断上升，带来了沉重的医疗负担。然而，目前仍缺乏有效的预防和治疗策略。成纤维细胞生长因子 21（FGF21）是人类 FGF 超家族的一员，是维持代谢内稳态的关键蛋白，包括减少脂肪量和降低高血糖、胰岛素抵抗和血脂异常。在这里，我们综述了 FGF21 的现有调控机制，总结了它在肥胖、糖尿病、血脂异常和高血压中的作用，并讨论了 FGF21 作为治疗代谢综合征的潜在靶点的可能性。
